Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder

Unyime O. Nseyo, Bryan Shumaker, Eric A. Klein, Karole Sutherland, Anton Bueschen, E. David Crawford, Guy Drouin, Asher Hoodin, Robert Huben, Niall Heney, Michael Jewett, Michael Koch, Donald Lamm, John Oliver, K. Psihramis, Joseph Smith

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Purpose: Photodynamic therapy combines a photosensitizer, such as porfimer sodium (Photofrin), with red laser light (630 nm.) to destroy cancer cells. Investigators have reported the effectiveness of photodynamic therapy in the treatment of patients with recurrent superficial bladder cancer. We assess the safety and efficacy of 1 or 2 photodynamic treatments using porfimer sodium and controlled uniform laser light (630 nm.) as an alternative to cystectomy in patients with refractory vesical carcinoma in situ of the bladder. Materials and Methods: A total of 36 patients with carcinoma in situ were treated with whole bladder photodynamic therapy as an alternative to cystectomy. In all patients at least i course of bacillus Calmette-Guerin (BCG) had failed. Each patient received a single whole bladder photodynamic therapy treatment, consisting of 2 mg./kg, porfimer sodium intravenously followed 40 to 50 hours later by intravesical red light (630 nm.) at 15 J./cm.2. Post-photodynamic therapy evaluations included weekly telephone contact to assess acute adverse reactions, and assessment of efficacy and bladder toxicity at 3 months and quarterly thereafter. Results: At initial clinical evaluation at 3 months 58% of the patients had a complete response as indicated by negative cystoscopy, bladder biopsy and urine cytology but in 42% treatment failed. At a mean followup of 12 months (range 9 to 48) 10 of the 21 complete responders had recurrence for an overall durable response rate of 31%. Fourteen patients subsequently underwent cystectomy for persistent carcinoma in situ (12) and carcinoma in situ recurrence (2). Of the 36 patients 7 experienced bladder contracture. Conclusions: The initial results are encouraging for a single whole bladder photodynamic treatment of patients in whom prior intravesical therapy for carcinoma in situ has failed. While followup is short, porfimer sodium photodynamic therapy appears potentially promising as an alternative to cystectomy in patients with refractory carcinoma in situ.

Original languageEnglish (US)
Pages (from-to)39-44
Number of pages6
JournalJournal of Urology
Volume160
Issue number1
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Dihematoporphyrin Ether
Transitional Cell Carcinoma
Cystectomy
Carcinoma in Situ
Photochemotherapy
Urinary Bladder
Light
Lasers
Therapeutics
Recurrence
Cystoscopy
Photosensitizing Agents
Contracture
Mycobacterium bovis
Telephone
Urinary Bladder Neoplasms
Cell Biology
Research Personnel

Keywords

  • Bladder neoplasms
  • Carcinoma in situ
  • Photosensitizing agents
  • Phototherapy

ASJC Scopus subject areas

  • Urology

Cite this

Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. / Nseyo, Unyime O.; Shumaker, Bryan; Klein, Eric A.; Sutherland, Karole; Bueschen, Anton; Crawford, E. David; Drouin, Guy; Hoodin, Asher; Huben, Robert; Heney, Niall; Jewett, Michael; Koch, Michael; Lamm, Donald; Oliver, John; Psihramis, K.; Smith, Joseph.

In: Journal of Urology, Vol. 160, No. 1, 1998, p. 39-44.

Research output: Contribution to journalArticle

Nseyo, UO, Shumaker, B, Klein, EA, Sutherland, K, Bueschen, A, Crawford, ED, Drouin, G, Hoodin, A, Huben, R, Heney, N, Jewett, M, Koch, M, Lamm, D, Oliver, J, Psihramis, K & Smith, J 1998, 'Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder', Journal of Urology, vol. 160, no. 1, pp. 39-44. https://doi.org/10.1016/S0022-5347(01)63021-0
Nseyo, Unyime O. ; Shumaker, Bryan ; Klein, Eric A. ; Sutherland, Karole ; Bueschen, Anton ; Crawford, E. David ; Drouin, Guy ; Hoodin, Asher ; Huben, Robert ; Heney, Niall ; Jewett, Michael ; Koch, Michael ; Lamm, Donald ; Oliver, John ; Psihramis, K. ; Smith, Joseph. / Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. In: Journal of Urology. 1998 ; Vol. 160, No. 1. pp. 39-44.
@article{d319e1e259544362b20985486da7492a,
title = "Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder",
abstract = "Purpose: Photodynamic therapy combines a photosensitizer, such as porfimer sodium (Photofrin), with red laser light (630 nm.) to destroy cancer cells. Investigators have reported the effectiveness of photodynamic therapy in the treatment of patients with recurrent superficial bladder cancer. We assess the safety and efficacy of 1 or 2 photodynamic treatments using porfimer sodium and controlled uniform laser light (630 nm.) as an alternative to cystectomy in patients with refractory vesical carcinoma in situ of the bladder. Materials and Methods: A total of 36 patients with carcinoma in situ were treated with whole bladder photodynamic therapy as an alternative to cystectomy. In all patients at least i course of bacillus Calmette-Guerin (BCG) had failed. Each patient received a single whole bladder photodynamic therapy treatment, consisting of 2 mg./kg, porfimer sodium intravenously followed 40 to 50 hours later by intravesical red light (630 nm.) at 15 J./cm.2. Post-photodynamic therapy evaluations included weekly telephone contact to assess acute adverse reactions, and assessment of efficacy and bladder toxicity at 3 months and quarterly thereafter. Results: At initial clinical evaluation at 3 months 58{\%} of the patients had a complete response as indicated by negative cystoscopy, bladder biopsy and urine cytology but in 42{\%} treatment failed. At a mean followup of 12 months (range 9 to 48) 10 of the 21 complete responders had recurrence for an overall durable response rate of 31{\%}. Fourteen patients subsequently underwent cystectomy for persistent carcinoma in situ (12) and carcinoma in situ recurrence (2). Of the 36 patients 7 experienced bladder contracture. Conclusions: The initial results are encouraging for a single whole bladder photodynamic treatment of patients in whom prior intravesical therapy for carcinoma in situ has failed. While followup is short, porfimer sodium photodynamic therapy appears potentially promising as an alternative to cystectomy in patients with refractory carcinoma in situ.",
keywords = "Bladder neoplasms, Carcinoma in situ, Photosensitizing agents, Phototherapy",
author = "Nseyo, {Unyime O.} and Bryan Shumaker and Klein, {Eric A.} and Karole Sutherland and Anton Bueschen and Crawford, {E. David} and Guy Drouin and Asher Hoodin and Robert Huben and Niall Heney and Michael Jewett and Michael Koch and Donald Lamm and John Oliver and K. Psihramis and Joseph Smith",
year = "1998",
doi = "10.1016/S0022-5347(01)63021-0",
language = "English (US)",
volume = "160",
pages = "39--44",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder

AU - Nseyo, Unyime O.

AU - Shumaker, Bryan

AU - Klein, Eric A.

AU - Sutherland, Karole

AU - Bueschen, Anton

AU - Crawford, E. David

AU - Drouin, Guy

AU - Hoodin, Asher

AU - Huben, Robert

AU - Heney, Niall

AU - Jewett, Michael

AU - Koch, Michael

AU - Lamm, Donald

AU - Oliver, John

AU - Psihramis, K.

AU - Smith, Joseph

PY - 1998

Y1 - 1998

N2 - Purpose: Photodynamic therapy combines a photosensitizer, such as porfimer sodium (Photofrin), with red laser light (630 nm.) to destroy cancer cells. Investigators have reported the effectiveness of photodynamic therapy in the treatment of patients with recurrent superficial bladder cancer. We assess the safety and efficacy of 1 or 2 photodynamic treatments using porfimer sodium and controlled uniform laser light (630 nm.) as an alternative to cystectomy in patients with refractory vesical carcinoma in situ of the bladder. Materials and Methods: A total of 36 patients with carcinoma in situ were treated with whole bladder photodynamic therapy as an alternative to cystectomy. In all patients at least i course of bacillus Calmette-Guerin (BCG) had failed. Each patient received a single whole bladder photodynamic therapy treatment, consisting of 2 mg./kg, porfimer sodium intravenously followed 40 to 50 hours later by intravesical red light (630 nm.) at 15 J./cm.2. Post-photodynamic therapy evaluations included weekly telephone contact to assess acute adverse reactions, and assessment of efficacy and bladder toxicity at 3 months and quarterly thereafter. Results: At initial clinical evaluation at 3 months 58% of the patients had a complete response as indicated by negative cystoscopy, bladder biopsy and urine cytology but in 42% treatment failed. At a mean followup of 12 months (range 9 to 48) 10 of the 21 complete responders had recurrence for an overall durable response rate of 31%. Fourteen patients subsequently underwent cystectomy for persistent carcinoma in situ (12) and carcinoma in situ recurrence (2). Of the 36 patients 7 experienced bladder contracture. Conclusions: The initial results are encouraging for a single whole bladder photodynamic treatment of patients in whom prior intravesical therapy for carcinoma in situ has failed. While followup is short, porfimer sodium photodynamic therapy appears potentially promising as an alternative to cystectomy in patients with refractory carcinoma in situ.

AB - Purpose: Photodynamic therapy combines a photosensitizer, such as porfimer sodium (Photofrin), with red laser light (630 nm.) to destroy cancer cells. Investigators have reported the effectiveness of photodynamic therapy in the treatment of patients with recurrent superficial bladder cancer. We assess the safety and efficacy of 1 or 2 photodynamic treatments using porfimer sodium and controlled uniform laser light (630 nm.) as an alternative to cystectomy in patients with refractory vesical carcinoma in situ of the bladder. Materials and Methods: A total of 36 patients with carcinoma in situ were treated with whole bladder photodynamic therapy as an alternative to cystectomy. In all patients at least i course of bacillus Calmette-Guerin (BCG) had failed. Each patient received a single whole bladder photodynamic therapy treatment, consisting of 2 mg./kg, porfimer sodium intravenously followed 40 to 50 hours later by intravesical red light (630 nm.) at 15 J./cm.2. Post-photodynamic therapy evaluations included weekly telephone contact to assess acute adverse reactions, and assessment of efficacy and bladder toxicity at 3 months and quarterly thereafter. Results: At initial clinical evaluation at 3 months 58% of the patients had a complete response as indicated by negative cystoscopy, bladder biopsy and urine cytology but in 42% treatment failed. At a mean followup of 12 months (range 9 to 48) 10 of the 21 complete responders had recurrence for an overall durable response rate of 31%. Fourteen patients subsequently underwent cystectomy for persistent carcinoma in situ (12) and carcinoma in situ recurrence (2). Of the 36 patients 7 experienced bladder contracture. Conclusions: The initial results are encouraging for a single whole bladder photodynamic treatment of patients in whom prior intravesical therapy for carcinoma in situ has failed. While followup is short, porfimer sodium photodynamic therapy appears potentially promising as an alternative to cystectomy in patients with refractory carcinoma in situ.

KW - Bladder neoplasms

KW - Carcinoma in situ

KW - Photosensitizing agents

KW - Phototherapy

UR - http://www.scopus.com/inward/record.url?scp=0032324212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032324212&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)63021-0

DO - 10.1016/S0022-5347(01)63021-0

M3 - Article

C2 - 9628601

AN - SCOPUS:0032324212

VL - 160

SP - 39

EP - 44

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -